We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in PhoreMost as part of a £4m series ‘A’ round of equity and grant funding, of which the equity tranche was led by Amadeus Capital Partners and the Abcam founder, Jonathan Milner.

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

PhoreMost believes it is uniquely placed to deliver a pipeline of highly selective and patient-specific drugs for cancer and other conditions currently lacking therapeutic options. The company is seeking to develop ways in which to apply such treatments cost-effectively.